Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN

ILLUMINA, INC.

(ILMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences

01/02/2020 | 04:48pm EST
The offices of gene sequencing company Illumina Inc are shown in San Diego, California

Illumina Inc on Thursday agreed to terminate the $1.2 billion (913.4 million pounds) deal to buy smaller rival Pacific Biosciences of California Inc, weeks after the U.S. competition watchdog filed a complaint to block the purchase.

Gene sequencing company Illumina would pay Pacific Biosciences $98 million for the terminated deal, which was announced in 2018 and had attracted scrutiny from antitrust authorities in the United States and UK, both the companies said in a joint statement.

Illumina is a major player in the nascent gene sequencing space, which involves analysing the genome, and can among other uses, identify inherited disorders and markers of disease progression.

In its complaint last month, the U.S. Federal Trade Commission raised concerns that Illumina wanted the deal in order to prevent Pacific Biosciences from developing into a competitor in the market for next-generation DNA sequencing.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DNA OYJ 0.00%End-of-day quote.-0.10%
ILLUMINA, INC. 1.43% 376.35 Delayed Quote.1.72%
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. -2.11% 36.925 Delayed Quote.42.35%
SPACE CO.,LTD. -0.25% 808 End-of-day quote.2.41%
TELENOR ASA 0.03% 146.2 Real-time Quote.0.17%
All news about ILLUMINA, INC.
01/14Qiagen warns against using standard tests to track coronavirus variants
RE
01/12ILLUMINA, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
01/11ILLUMINA : New Bioinformatics Solution Powers Multi-Omics Discovery at Massive S..
BU
01/11ILLUMINA : Announces New and Expanded Oncology Partnerships with Bristol Myers S..
BU
01/11Grail in Minimum Residual Disease Collaborations With Amgen, AstraZeneca, Bri..
DJ
01/11ILLUMINA, INC. : SEC Filing 8K
CO
01/07ILLUMINA : Insider Sales at Illumina (ILMN) are Significant and Extend the Selli..
MT
01/06INSIDER TRENDS : Insider Adds to 90-Day Selling Trend at Illumina
MT
01/06INSIDER TRENDS : Selling By Insiders Lingers at Illumina
MT
01/06ILLUMINA, INC. : Report
CO
More news
Financials (USD)
Sales 2020 3 226 M - -
Net income 2020 551 M - -
Net cash 2020 2 230 M - -
P/E ratio 2020 101x
Yield 2020 -
Capitalization 54 947 M 54 947 M -
EV / Sales 2020 16,3x
EV / Sales 2021 13,7x
Nbr of Employees 7 700
Free-Float 75,1%
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | ILMN | US4523271090 | MarketScreener
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 322,31 $
Last Close Price 376,35 $
Spread / Highest target 10,3%
Spread / Average Target -14,4%
Spread / Lowest Target -33,6%
EPS Revisions
Managers and Directors
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Robert P. Ragusa Senior Vice President-Global Quality & Operations
Sam A. Samad Chief Financial Officer & Senior Vice President
Phillip G. Febbo Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.1.72%54 947
THERMO FISHER SCIENTIFIC6.68%199 412
DANAHER CORPORATION6.58%168 182
INTUITIVE SURGICAL, INC.-4.85%91 508
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.3.75%82 922
SIEMENS HEALTHINEERS AG3.86%56 444